Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
Kiniksa Pharmaceuticals International NASDAQ: KNSA said its commercialized recurrent pericarditis treatment ARCALYST continues to grow, while the company has begun a pivotal Phase 3 study of follow-on candidate KPL-387.
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
KNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3 to support its next growth driver.
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Kiniksa Pharmaceuticals International, plc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 184 | $7,393.15 | $14,077.84 | $6,684.69 | 90.42% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 10,634 | $680,040 | $808,822.02 | $128,782.02 | 18.94% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 3 | $116.49 | $233.4 | $116.91 | 100.36% |
| BG Bart Gancher Intech Investment Management LLC | 7,464 | $477,322.8 | $567,711.83 | $90,389.03 | 18.94% |
 John H. Burbank III Passport Capital LLC | 2.83M | $53.4M | $217.56M | $164.16M | 307.45% |
Kiniksa Pharmaceuticals International, plc Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Paul Choi Goldman Sachs | 103.03 | $6,485.25 | $7,829.01 | $1,343.76 | 20.72% |
| EFV Eva Fortea Verdejo Wells Fargo | 373.66 | $19,842.94 | $28,588.61 | $8,745.67 | 44.07% |
Kiniksa Pharmaceuticals International, plc (KNSA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kiniksa Pharmaceuticals International, plc ever had a stock split?
Kiniksa Pharmaceuticals International, plc Profile
| Biotechnology Industry | Healthcare Sector | Sanj K. Patel CEO | NASDAQ (NGS) Exchange | G52796105 CUSIP |
| GB Country | 366 Employees | - Last Dividend | - Last Split | 24 May 2018 IPO Date |
Overview
Kiniksa Pharmaceuticals, Ltd. is a dynamic biopharmaceutical company dedicated to the discovery, acquisition, development, and commercialization of innovative therapeutic medicines. Established in 2015 and headquartered in Hamilton, Bermuda, Kiniksa is propelled by a mission to address the profound needs of patients suffering from debilitating diseases that remain largely unmet globally. The company’s approach emphasizes a patient-centric model, aiming to bring significant advancements in treatment options across various disease states characterized by high medical necessity.
Products and Services
ARCALYST: ARCALYST represents a pioneering therapeutic approach for patients with recurrent pericarditis, a persistent and painful inflammatory cardiovascular condition. As a dual inhibitor targeting both interleukin-1alpha and interleukin-1beta, ARCALYST offers a novel treatment pathway, potentially providing much-needed relief for those afflicted by this challenging disease.
Mavrilimumab: This monoclonal antibody inhibitor has successfully reached the completion of Phase II clinical trials, targeting the treatment of giant cell arteritis. Giant cell arteritis is a severe autoimmune disease characterized by inflammation of the large and medium arteries, typically affecting the head. Mavrilimumab represents a significant stride forward in offering an innovative therapeutic option for patients grappling with this condition.
Vixarelimab: In the pipeline for Kiniksa Pharmaceuticals is Vixarelimab, another monoclonal antibody, currently undergoing a Phase 2b clinical trial. It’s aimed at addressing the needs of patients suffering from prurigo nodularis, a chronic inflammatory skin disease marked by itchy nodules. Vixarelimab could significantly improve the quality of life for individuals dealing with the unrelenting itch and discomfort of prurigo nodularis.
KPL-404: A testament to Kiniksa’s innovative spirit, KPL-404 is in development to inhibit the CD40-CD154 interaction. This interaction is crucial for B-cell maturation and the immune response, making KPL-404 a hopeful candidate for altering the course of diseases requiring a modulation of the immune system. With its focus on the T-cell co-stimulatory signal critical for various immune responses, KPL-404 could pave the way for novel treatments in autoimmune diseases and beyond.
